On July 30, Abivax S.A. rose 5.18% in regular trading, trading at $124.4/share, with turnover of $55.49 million. The rally was driven by Morgan Stanley significantly raising its price target on the company from $132 to $180 while maintaining an Overweight rating.

According to Morgan Stanley's research note, obefazimod — Abivax's lead drug candidate for ulcerative colitis — has demonstrated promising clinical results, with key opinion leaders expressing unanimous support for the drug's efficacy profile, particularly on endoscopic measures. The firm noted that sentiment on lingering regulatory and labeling concerns has improved as clinical data has come in, suggesting broad opportunity for commercial uptake.

Additionally, Abivax closed a $920 million ADS offering in early July, generating estimated net proceeds of approximately $874.1 million. The company stated the funds will support operations into Q4 of 2029 and finance the potential U.S. commercialization of obefazimod. The consensus mean price target among analysts polled stands at $162.06, well above the current trading level.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)